Physician profile
Rolando E Diaz
NPI 1336179985
$1,599.02
in general payments reported to CMS, 2019-2025
23 companies · $308 in 2025
The $308 reported for 2025 was more than what 76% of General Practice providers received nationally (typical 2025 total: $105).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $210 · 2020: $111 · 2021: $94.57 · 2022: $277 · 2023: $175 · 2024: $423 · 2025: $308.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $906.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $906.28 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exact Sciences Corporation | $308.05 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Lundbeck LLC | $244.50 | 2023-2025 | Rexulti |
| Sanofi-Aventis U.S. LLC | $143.89 | 2019-2020 | |
| Novo Nordisk INC | $136.21 | 2019-2025 | Ozempic, Rybelsus |
| E.R. Squibb & Sons, L.L.C. | $115.70 | 2022 | |
| Phadia US INC. | $84.66 | 2020-2024 | Immunocap |
| Bayer Healthcare Pharmaceuticals INC. | $77.51 | 2022-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $76.30 | 2021-2022 | |
| Lilly USA, LLC | $70.91 | 2019-2025 | Mounjaro, Zepbound |
| Merck Sharp & Dohme LLC | $65.10 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $41.59 | 2022-2024 | Flumist Quadrivalent |
| Curonix LLC | $34.91 | 2023 | Pns Freedom-4a Permanent Neurostimulator Receiver Kit Channel A |
| Abbvie INC. | $28.52 | 2022 | |
| Sumitomo Pharma America, INC. | $24.30 | 2025 | Gemtesa |
| Medtronic, INC. | $20.09 | 2024 | Kyphon Express II Kyphopak Tray |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $19.94 | 2024 | Repatha, Otezla |
| Pfizer INC. | $18.60 | 2023 | |
| Amarin Pharma, INC. | $17.08 | 2021 | |
| Novartis Pharmaceuticals Corporation | $15.28 | 2022 | |
| Evoke Pharma, INC. | $14.81 | 2022 | |
| Sanofi Pasteur INC. | $14.30 | 2021 | |
| Horizon Therapeutics Plc | $13.85 | 2019 | |
| Janssen Pharmaceuticals, INC | $12.92 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rolando Diaz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.